NO982097L - Peptider - Google Patents

Peptider

Info

Publication number
NO982097L
NO982097L NO982097A NO982097A NO982097L NO 982097 L NO982097 L NO 982097L NO 982097 A NO982097 A NO 982097A NO 982097 A NO982097 A NO 982097A NO 982097 L NO982097 L NO 982097L
Authority
NO
Norway
Prior art keywords
peptides
Prior art date
Application number
NO982097A
Other languages
English (en)
Other versions
NO982097D0 (no
NO315238B1 (no
Inventor
Gustav Gaudernack
Ingvil Saeterdal
Jon Amund Eriksen
Mona Moeller
Marianne Klemp Gjertsen
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19982097A priority Critical patent/NO315238B1/no
Publication of NO982097D0 publication Critical patent/NO982097D0/no
Priority to US09/674,973 priority patent/US6759046B1/en
Priority to PL99344341A priority patent/PL344341A1/xx
Priority to CNB998073555A priority patent/CN100355781C/zh
Priority to JP2000548356A priority patent/JP4591983B2/ja
Priority to EP99940722.4A priority patent/EP1078000B1/en
Priority to AU54516/99A priority patent/AU755712B2/en
Priority to HU0101432A priority patent/HUP0101432A3/hu
Priority to CA2327549A priority patent/CA2327549C/en
Priority to ES10183767.2T priority patent/ES2463825T3/es
Priority to EP10183767.2A priority patent/EP2374814B1/en
Priority to PCT/NO1999/000143 priority patent/WO1999058552A2/en
Priority to ARP990102199A priority patent/AR018346A1/es
Publication of NO982097L publication Critical patent/NO982097L/no
Priority to HK01107827A priority patent/HK1036997A1/xx
Publication of NO315238B1 publication Critical patent/NO315238B1/no
Priority to US10/776,224 priority patent/US7192927B2/en
Priority to US11/498,194 priority patent/US7863244B2/en
Priority to US12/983,510 priority patent/US8614177B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19982097A 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy NO315238B1 (no)

Priority Applications (17)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
PCT/NO1999/000143 WO1999058552A2 (en) 1998-05-08 1999-05-03 Peptides that ellicit t, cellular immunity
CA2327549A CA2327549C (en) 1998-05-08 1999-05-03 Peptides that induce t cell responses
EP10183767.2A EP2374814B1 (en) 1998-05-08 1999-05-03 Peptides that ellicit T cellular immunity
CNB998073555A CN100355781C (zh) 1998-05-08 1999-05-03 肽
JP2000548356A JP4591983B2 (ja) 1998-05-08 1999-05-03 ペプチド
EP99940722.4A EP1078000B1 (en) 1998-05-08 1999-05-03 Peptides that ellicit t cellular immunity
AU54516/99A AU755712B2 (en) 1998-05-08 1999-05-03 Peptides
HU0101432A HUP0101432A3 (en) 1998-05-08 1999-05-03 Peptides that ellicit, cellular immunity
US09/674,973 US6759046B1 (en) 1998-05-08 1999-05-03 Peptides
ES10183767.2T ES2463825T3 (es) 1998-05-08 1999-05-03 Péptidos que provocan inmunidad celular T
PL99344341A PL344341A1 (en) 1998-05-08 1999-05-03 Peptides
ARP990102199A AR018346A1 (es) 1998-05-08 1999-05-10 Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid
HK01107827A HK1036997A1 (en) 1998-05-08 2001-11-08 Peptides
US10/776,224 US7192927B2 (en) 1998-05-08 2004-02-12 Peptides
US11/498,194 US7863244B2 (en) 1998-05-08 2006-08-03 Peptides
US12/983,510 US8614177B2 (en) 1998-05-08 2011-01-03 Peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy

Publications (3)

Publication Number Publication Date
NO982097D0 NO982097D0 (no) 1998-05-08
NO982097L true NO982097L (no) 1999-11-09
NO315238B1 NO315238B1 (no) 2003-08-04

Family

ID=19902021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy

Country Status (13)

Country Link
US (4) US6759046B1 (no)
EP (2) EP1078000B1 (no)
JP (1) JP4591983B2 (no)
CN (1) CN100355781C (no)
AR (1) AR018346A1 (no)
AU (1) AU755712B2 (no)
CA (1) CA2327549C (no)
ES (1) ES2463825T3 (no)
HK (1) HK1036997A1 (no)
HU (1) HUP0101432A3 (no)
NO (1) NO315238B1 (no)
PL (1) PL344341A1 (no)
WO (1) WO1999058552A2 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
GB2361701A (en) * 2000-04-28 2001-10-31 Norsk Hydro As DNA polymerase delta mutants
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
WO2003020306A1 (fr) * 2001-08-29 2003-03-13 Kyogo Itoh Desensibilisants
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
EP1369126A1 (en) * 2002-04-18 2003-12-10 MTM Laboratories AG Use of coding microsatellite region frameshift mutation-derived peptides for treating cancer
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
CN101052408B (zh) * 2004-09-07 2013-03-27 伯纳姆研究院 选择性锚定到心脏脉管系统上的肽和相关结合物和方法
US7501486B2 (en) * 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
MX2007004662A (es) * 2004-10-18 2007-11-23 Globeimmune Inc Terapia basada en levaduras para infeccion cronica por hepatitis c.
JP2009500454A (ja) * 2005-07-11 2009-01-08 グローブイミューン， インコーポレイテッド 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法
WO2007101227A2 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
DK2059256T3 (en) 2006-08-11 2016-12-05 Life Sciences Res Partners Vzw Immunogenic peptides AND USE THEREOF FOR THE IMMUNE DISORDERS
MX2009010066A (es) * 2007-03-19 2009-10-12 Globeimmune Inc Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
ES2545886T3 (es) 2008-02-14 2015-09-16 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
ES2627882T3 (es) 2008-02-14 2017-07-31 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
AU2009214038B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
EP2249864B1 (en) * 2008-02-14 2016-05-04 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
WO2009101207A1 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
BRPI1008971A2 (pt) 2009-03-09 2016-03-15 Bioatla Llc métodos para preparar uma proteína biológica condicionalmente ativa, e um modificador de resposta biológica condicionalmente ativo, proteína biológica condicionalmente ativa, e, composição farmacêutica
DK2643345T5 (da) 2010-11-25 2021-05-17 Imnate Sarl Immunogene peptider til anvendelse til forebyggelse og/eller behandling af infektionssygdomme, autoimmune sygdomme, immunresponser på allofaktorer, allergisygdomme, tumorer, transplantatafstødning og immunresponser på virusvektorer anvendt til genterapi eller genvaccination
ES2665576T3 (es) * 2011-10-28 2018-04-26 Oncotherapy Science, Inc. Péptidos TOPK y vacunas que los incluyen
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US20150045291A1 (en) * 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
US9205140B2 (en) 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
CN113956349B (zh) 2014-11-26 2024-09-06 美国卫生和人力服务部 抗突变的kras的t细胞受体
WO2016183486A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP2016028025A (ja) * 2015-07-29 2016-02-25 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
WO2017050966A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
AU2016340763B2 (en) * 2015-10-23 2021-04-22 Jai Prakash Integrin binding peptides and uses thereof
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
EP3779447B1 (en) * 2016-03-15 2023-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
IL262286B2 (en) 2016-04-19 2023-12-01 Imcyse Sa Novel immunogenic peptides that bind CD1D
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
US11136368B2 (en) * 2016-08-23 2021-10-05 The Cleveland Clinic Foundation Cancer treatment using CX26 blocking peptides
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2018157773A1 (zh) * 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US20210213116A1 (en) 2018-07-26 2021-07-15 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
US20210252123A1 (en) 2018-07-26 2021-08-19 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
US20210187088A1 (en) 2018-07-26 2021-06-24 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020239937A1 (en) * 2019-05-29 2020-12-03 Hubro Therapeutics As Peptides
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN113061165A (zh) * 2020-01-02 2021-07-02 厦门大学 EB病毒BNLF2b基因编码多肽及其检测用途
WO2021142007A1 (en) * 2020-01-09 2021-07-15 Arizona Board Of Regents On Behalf Of Arizona State University Antibodies and method of producing antibodies
AU2021279327A1 (en) * 2020-05-28 2022-12-22 Hubro Therapeutics As A peptide cocktail
WO2024052542A2 (en) * 2022-09-09 2024-03-14 Hubro Therapeutics As A peptide cocktail

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9410922D0 (en) * 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US5958684A (en) 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US5973018A (en) * 1995-10-04 1999-10-26 Owens-Corning Fiberglas Technology, Inc. Process for producing shaped phenolic foams
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU4907797A (en) 1996-10-10 1998-05-05 Wistar Institute Of Anatomy And Biology, The Methods and compositions for inducing a protective immune response to cancers
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
CA2327549A1 (en) 1999-11-18
HUP0101432A3 (en) 2004-01-28
CA2327549C (en) 2014-10-07
CN1305495A (zh) 2001-07-25
PL344341A1 (en) 2001-11-05
CN100355781C (zh) 2007-12-19
US6759046B1 (en) 2004-07-06
US8614177B2 (en) 2013-12-24
AU5451699A (en) 1999-11-29
EP1078000A2 (en) 2001-02-28
US20050074849A1 (en) 2005-04-07
WO1999058552A2 (en) 1999-11-18
NO982097D0 (no) 1998-05-08
ES2463825T3 (es) 2014-05-29
EP2374814B1 (en) 2014-03-19
NO315238B1 (no) 2003-08-04
JP4591983B2 (ja) 2010-12-01
US20070004632A1 (en) 2007-01-04
US7863244B2 (en) 2011-01-04
AU755712B2 (en) 2002-12-19
US7192927B2 (en) 2007-03-20
AR018346A1 (es) 2001-11-14
EP2374814A3 (en) 2012-01-11
JP2002519999A (ja) 2002-07-09
EP1078000B1 (en) 2017-03-29
EP2374814A2 (en) 2011-10-12
US20110105721A1 (en) 2011-05-05
HUP0101432A2 (hu) 2001-08-28
WO1999058552A3 (en) 2000-03-02
HK1036997A1 (en) 2002-01-25

Similar Documents

Publication Publication Date Title
NO982097L (no) Peptider
NO982098D0 (no) Peptider
ATE341990T1 (de) Sigmidoskop
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
DE59911453D1 (de) Aktivkohlefilter
PT1080086E (pt) Dihidropirimidinas
DE59902874D1 (de) Buchsenkontakt
DE59907306D1 (de) Fadenchangierung
NO994559L (no) Löftemotor
DE59911683D1 (de) Fahrzeugschliessanlage
NO20001494L (no) Overligger
ATE262513T1 (de) Benzoylpyridazine
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59908057D1 (de) Underdruckhandhabungseinrichung
FI980187A0 (fi) Vattenturbinsystem
FR2791348B1 (fr) POLYPEPTIDE Npt2B
DE59807217D1 (de) Nadellager
ATE295417T1 (de) Angiostatin-bindendes protein
DE19842103B4 (de) Stanznietzuführung
DE59808995D1 (de) Endomikroskopsystem
DE59903616D1 (de) Rollenwicklerwalze
NO20012283D0 (no) Koblede peptider
NO20013933D0 (no) Peptider

Legal Events

Date Code Title Description
MK1K Patent expired